HCV treatment Epclusa·Vosevi start pricing negotiations

By Lee, Tak-Sun | translator Alice Kang

22.09.22 16:12:24

가나다라 0

Gilead attempts to turn around the market taken away by Abbvie with new products

Received conditional approval at DREC meeting in July... assumed to have accepted a price lower than the evaluated amount

The National Health Insurance Service is known to be conducting pricing negotiations with Gilead Science Korea for the company’s new Hepatitis C treatments, ‘Vosevi (sofosbuvir/velpatasvir/voxilaprevir)’ and ‘Epclusa (sofosbuvir/velpatasvir).’

The two drugs received conditional approval from the Drug Reimbursement Evaluation Committee in July this year.

According to industry sources on the 22nd, the NHIS disclosed the negotiation status above while updating the list of new drugs subject to drug pricing negotiations on the NHIS webpage.

Epclusa is a new drug that was approved in February, and Vosevi in March by the Ministry of Food and Safety. Gilead, which used to do

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)